CLINICAL_TRIALS
trial_result
· 2016-04-27
Clinical Trial Update: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum [Phase 3]
Summary
A 2-year, open-label safety extension study of gevokizumab in patients with pyoderma gangrenosum has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: XOMA (US) LLC | Conditions: Pyoderma Gangrenosum | Phase 3 | Status: TERMINATED